Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi (SAN)
Price€73.26Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €43.63B | €41.08B | €37.82B | €37.65B | €37.76B | €36.04B | €36.13B | €34.46B | €35.07B | €33.81B | €34.06B |
| Gross profit | €33.67B | €31.08B | €28.99B | €28.68B | €26.92B | €25.21B | €25.65B | €24.24B | €24.61B | €24.00B | €23.94B |
| Gross margin | 77.17% | 75.66% | 76.66% | 76.17% | 71.29% | 69.95% | 71.01% | 70.34% | 70.16% | 70.97% | 70.29% |
| Research & development | €7.84B | €7.39B | €6.51B | €6.50B | €5.69B | €5.53B | €6.02B | €5.89B | €5.47B | €5.17B | €5.08B |
| Operating expenses | €27.32B | €23.83B | €22.03B | €18.52B | €18.79B | €11.10B | €22.60B | €19.57B | €18.80B | €17.46B | €18.32B |
| Operating income | €6.34B | €7.25B | €6.96B | €10.16B | €8.13B | €14.11B | €3.05B | €4.68B | €5.80B | €6.53B | €5.62B |
| Operating margin | 14.54% | 17.65% | 18.40% | 26.99% | 21.52% | 39.16% | 8.45% | 13.57% | 16.55% | 19.32% | 16.51% |
| EBITDA | €12.48B | €10.99B | €11.32B | €13.51B | — | — | — | — | — | — | — |
| EBITDA margin | 28.60% | 26.75% | 29.94% | 35.88% | — | — | — | — | — | — | — |
| Net income | €7.85B | €5.62B | €5.44B | €8.48B | €6.28B | €12.33B | €2.79B | €4.41B | €8.54B | €4.80B | €4.39B |
| Net profit margin | 18.00% | 13.68% | 14.37% | 22.53% | 16.63% | 34.21% | 7.71% | 12.80% | 24.34% | 14.20% | 12.88% |
| Basic EPSper basic share | €6.40 | €4.44 | €4.31 | €6.69 | €4.97 | €9.81 | €2.24 | €3.45 | €6.70 | €3.66 | €3.28 |
| Diluted EPSper diluted share | €6.37 | €4.43 | €4.30 | €6.66 | €4.95 | €9.76 | €2.23 | €3.43 | €6.64 | €3.63 | €3.25 |